BR112020003541A2 - tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida - Google Patents

tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida Download PDF

Info

Publication number
BR112020003541A2
BR112020003541A2 BR112020003541-6A BR112020003541A BR112020003541A2 BR 112020003541 A2 BR112020003541 A2 BR 112020003541A2 BR 112020003541 A BR112020003541 A BR 112020003541A BR 112020003541 A2 BR112020003541 A2 BR 112020003541A2
Authority
BR
Brazil
Prior art keywords
patient
doses
bone
fact
acid sphingomyelinase
Prior art date
Application number
BR112020003541-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Ana Cristina Scheidt-Puga
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of BR112020003541A2 publication Critical patent/BR112020003541A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
BR112020003541-6A 2017-08-24 2018-08-22 tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida BR112020003541A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762549732P 2017-08-24 2017-08-24
US62/549,732 2017-08-24
EP17306720 2017-12-07
EP17306720.8 2017-12-07
PCT/IB2018/056346 WO2019038685A2 (en) 2017-08-24 2018-08-22 TREATMENT OF ABNORMAL BONE CONDITIONS IN PATIENTS WITH ACIDIC SPHINGOMYELASE DISEASE

Publications (1)

Publication Number Publication Date
BR112020003541A2 true BR112020003541A2 (pt) 2020-09-01

Family

ID=63556374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020003541-6A BR112020003541A2 (pt) 2017-08-24 2018-08-22 tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida

Country Status (16)

Country Link
US (2) US11898175B2 (enExample)
EP (1) EP3672622B1 (enExample)
JP (3) JP7216075B2 (enExample)
KR (2) KR102769578B1 (enExample)
CN (2) CN118453843A (enExample)
AU (2) AU2018319565B2 (enExample)
BR (1) BR112020003541A2 (enExample)
CA (1) CA3073648A1 (enExample)
CO (1) CO2020001801A2 (enExample)
ES (1) ES2970423T3 (enExample)
IL (1) IL272757B2 (enExample)
MX (2) MX2020002106A (enExample)
PL (1) PL3672622T3 (enExample)
SG (1) SG11202001544VA (enExample)
TW (1) TWI791040B (enExample)
WO (1) WO2019038685A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2773133A1 (en) * 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy
PY1939780A (es) * 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
JP7568648B2 (ja) * 2019-05-31 2024-10-16 ジェンザイム・コーポレーション 二次元ｌｃ－ｍｓ／ｍｓシステム
CN112773779B (zh) * 2021-02-04 2022-08-16 上海交通大学医学院附属新华医院 氨溴索、千金藤和汉防已在治疗酸性鞘磷脂酶缺乏症中的应用
TW202403043A (zh) * 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
CN1302897A (zh) 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
US8158582B2 (en) * 2005-06-02 2012-04-17 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 deficiency
CA2773133A1 (en) * 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
WO2013130963A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
AR093908A1 (es) 2012-12-12 2015-06-24 Teva Pharma Fusion de la hormona de crecimiento humana y albumina, formulacion y usos de la misma
MX370570B (es) * 2013-06-07 2019-12-17 Genzyme Corp Marcador para trastornos de la esfingomielinasa acida y sus usos.
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy

Also Published As

Publication number Publication date
CN118453843A (zh) 2024-08-09
JP2023052459A (ja) 2023-04-11
AU2018319565B2 (en) 2025-02-20
WO2019038685A2 (en) 2019-02-28
MX2020002106A (es) 2020-07-14
AU2018319565A1 (en) 2020-04-09
IL272757B2 (en) 2024-07-01
NZ762860A (en) 2025-09-26
TWI791040B (zh) 2023-02-01
RU2020111649A (ru) 2021-09-24
JP2024050732A (ja) 2024-04-10
IL272757A (en) 2020-04-30
ES2970423T3 (es) 2024-05-28
IL272757B1 (en) 2024-03-01
US20240218338A1 (en) 2024-07-04
KR102769578B1 (ko) 2025-02-20
PL3672622T3 (pl) 2024-04-02
CA3073648A1 (en) 2019-02-28
JP7431356B2 (ja) 2024-02-14
EP3672622A2 (en) 2020-07-01
WO2019038685A3 (en) 2019-05-02
MX2023010908A (es) 2023-09-27
SG11202001544VA (en) 2020-03-30
JP2020531527A (ja) 2020-11-05
TW201919689A (zh) 2019-06-01
US20210139868A1 (en) 2021-05-13
JP7216075B2 (ja) 2023-01-31
EP3672622B1 (en) 2023-11-08
CN111344003B (zh) 2024-05-07
KR20250025051A (ko) 2025-02-20
CN111344003A (zh) 2020-06-26
AU2025203384A1 (en) 2025-05-29
KR20200044064A (ko) 2020-04-28
US11898175B2 (en) 2024-02-13
CO2020001801A2 (es) 2020-04-01

Similar Documents

Publication Publication Date Title
US20240218338A1 (en) Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients
Schuchman et al. Types A and B niemann-pick disease
Pogoryelova et al. GNE myopathy: from clinics and genetics to pathology and research strategies
Sasaki et al. Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype–genotype correlation in Japanese patients with pachydermoperiostosis
Hedrich et al. Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO)
Marcucci et al. Gaucher disease and bone manifestations
Otaify et al. Gnathodiaphyseal dysplasia: severe atypical presentation with novel heterozygous mutation of the anoctamin gene (ANO5)
Vissers et al. Whole‐exome sequencing detects somatic mutations of IDH1 in metaphyseal chondromatosis with D‐2‐hydroxyglutaric aciduria (MC‐HGA)
Ujhelyi et al. Bone mineral density and bone acquisition in children and young adults with cystic fibrosis: A follow‐up study
Rang et al. Re-imagining cystic fibrosis care: next generation thinking
Santi et al. Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model
RU2795570C2 (ru) Лечение патологических состояний кости у пациентов с дефицитом кислой сфингомиелиназы
BR122025022093A2 (pt) Uso de uma esfingomielinase ácida humana recombinante (rhasm) no tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida
Tsumiyama et al. A case of anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease complicated with tracheobronchial ulcers
Lee et al. Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA
Youssef et al. Outcome of enzyme replacement therapy for hematological and visceral manifestations in children with acid sphingomyelinase deficiency: a single center experience in upper Egypt
Kasapkara et al. The evaluation of skeletal manifestations in patients with Gaucher disease
Abdallah et al. The influence of vitamin D administration on the clinical presentation, body mass index, and osteoprotegerin (OPG) level in a sample of Egyptian children with familial Mediterranean fever
Alagia et al. ACID SPHINGOMYELINASE DEFICIENCY: A COMPLEX AND RARE DISORDER THAT NEEDS CLINICIANS'AWARENESS
Lang et al. Metabolic masqueraders of paediatric and adult rheumatic diseases
Kaur et al. A concise review on hypophosphatasia with case report
Osterbauer Clinical and Preclinical Characterization of Skeletal Muscle Aging
Laron et al. Recommended by ISPED and SIMA
Lierop Sclerostin: a key regulator of bone metabolism

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: SANOFI (FR)

B25A Requested transfer of rights approved

Owner name: GENZYME CORPORATION (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025022093-0 PROTOCOLO 870250093130 EM 10/10/2025 18:33.